S&P 500   4,342.61 (+0.29%)
DOW   34,109.08 (+0.11%)
QQQ   359.56 (+0.48%)
AAPL   174.87 (+0.54%)
MSFT   320.19 (+0.21%)
META   302.98 (+2.45%)
GOOGL   131.23 (+0.61%)
AMZN   131.23 (+1.47%)
TSLA   254.30 (-0.55%)
NVDA   415.41 (+1.28%)
NIO   8.60 (+1.78%)
BABA   88.19 (+4.85%)
AMD   96.61 (+0.52%)
T   15.11 (-1.31%)
F   12.57 (+3.03%)
MU   68.73 (+1.22%)
CGC   0.82 (+6.24%)
GE   112.92 (-0.06%)
DIS   82.55 (-0.22%)
AMC   7.78 (+1.04%)
PFE   32.63 (-0.67%)
PYPL   58.71 (+0.15%)
NFLX   381.87 (-0.59%)
S&P 500   4,342.61 (+0.29%)
DOW   34,109.08 (+0.11%)
QQQ   359.56 (+0.48%)
AAPL   174.87 (+0.54%)
MSFT   320.19 (+0.21%)
META   302.98 (+2.45%)
GOOGL   131.23 (+0.61%)
AMZN   131.23 (+1.47%)
TSLA   254.30 (-0.55%)
NVDA   415.41 (+1.28%)
NIO   8.60 (+1.78%)
BABA   88.19 (+4.85%)
AMD   96.61 (+0.52%)
T   15.11 (-1.31%)
F   12.57 (+3.03%)
MU   68.73 (+1.22%)
CGC   0.82 (+6.24%)
GE   112.92 (-0.06%)
DIS   82.55 (-0.22%)
AMC   7.78 (+1.04%)
PFE   32.63 (-0.67%)
PYPL   58.71 (+0.15%)
NFLX   381.87 (-0.59%)
S&P 500   4,342.61 (+0.29%)
DOW   34,109.08 (+0.11%)
QQQ   359.56 (+0.48%)
AAPL   174.87 (+0.54%)
MSFT   320.19 (+0.21%)
META   302.98 (+2.45%)
GOOGL   131.23 (+0.61%)
AMZN   131.23 (+1.47%)
TSLA   254.30 (-0.55%)
NVDA   415.41 (+1.28%)
NIO   8.60 (+1.78%)
BABA   88.19 (+4.85%)
AMD   96.61 (+0.52%)
T   15.11 (-1.31%)
F   12.57 (+3.03%)
MU   68.73 (+1.22%)
CGC   0.82 (+6.24%)
GE   112.92 (-0.06%)
DIS   82.55 (-0.22%)
AMC   7.78 (+1.04%)
PFE   32.63 (-0.67%)
PYPL   58.71 (+0.15%)
NFLX   381.87 (-0.59%)
S&P 500   4,342.61 (+0.29%)
DOW   34,109.08 (+0.11%)
QQQ   359.56 (+0.48%)
AAPL   174.87 (+0.54%)
MSFT   320.19 (+0.21%)
META   302.98 (+2.45%)
GOOGL   131.23 (+0.61%)
AMZN   131.23 (+1.47%)
TSLA   254.30 (-0.55%)
NVDA   415.41 (+1.28%)
NIO   8.60 (+1.78%)
BABA   88.19 (+4.85%)
AMD   96.61 (+0.52%)
T   15.11 (-1.31%)
F   12.57 (+3.03%)
MU   68.73 (+1.22%)
CGC   0.82 (+6.24%)
GE   112.92 (-0.06%)
DIS   82.55 (-0.22%)
AMC   7.78 (+1.04%)
PFE   32.63 (-0.67%)
PYPL   58.71 (+0.15%)
NFLX   381.87 (-0.59%)
NASDAQ:AGRX

Agile Therapeutics (AGRX) Stock Forecast, Price & News

$1.92
+0.19 (+10.73%)
(As of 10:00 AM ET)
Compare
Today's Range
$1.80
$2.09
50-Day Range
$1.73
$3.12
52-Week Range
$1.65
$16.00
Volume
46,079 shs
Average Volume
57,711 shs
Market Capitalization
$3.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00

Agile Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
593.6% Upside
$12.00 Price Target
Short Interest
Healthy
0.58% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.59
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.05) to ($1.06) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.35 out of 5 stars


AGRX stock logo

About Agile Therapeutics (NASDAQ:AGRX) Stock

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.

AGRX Price History

AGRX Stock News Headlines

The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Agile Therapeutics (NASDAQ: AGRX)
Why Agile Therapeutics Stock Is Trading Higher Today
See More Headlines
Receive AGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agile Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AGRX Company Calendar

Last Earnings
8/09/2023
Today
9/22/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AGRX
Fax
N/A
Employees
22
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.00
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+593.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-25,410,000.00
Net Margins
-201.02%
Pretax Margin
-116.82%

Debt

Sales & Book Value

Annual Sales
$10.88 million
Book Value
($6.83) per share

Miscellaneous

Free Float
1,916,000
Market Cap
$3.34 million
Optionable
Optionable
Beta
1.13
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Alfred F. AltomariMr. Alfred F. Altomari (Age 64)
    Chairman, Pres & CEO
    Comp: $644.4k
  • Mr. Geoffrey P. Gilmore (Age 57)
    Sr. VP & Chief Admin. Officer
    Comp: $478.92k
  • Dr. Paul Korner M.B.A. (Age 57)
    M.D., Sr. VP & Chief Medical Officer
    Comp: $480.4k
  • Mr. Scott M. Coiante (Age 56)
    CFO, Sr. VP & Treasurer
  • Matthew Riley
    Head of Investor Relations & Corp. Communications
  • Mr. Robert G. Conway M.E. (Age 65)
    Sr. VP and Chief Corp. Planning & Supply Chain Officer
  • Dr. Elizabeth Ijeoma Onyemelukwe Garner M.D. (Age 55)
    M.P.H., Consultant
  • Ms. Amy Welsh (Age 52)
    Sr. VP & Chief Commercial Officer
  • Joseph D'Urso
    Controller













AGRX Stock - Frequently Asked Questions

Should I buy or sell Agile Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AGRX shares.
View AGRX analyst ratings
or view top-rated stocks.

What is Agile Therapeutics' stock price forecast for 2023?

1 analysts have issued twelve-month price objectives for Agile Therapeutics' stock. Their AGRX share price forecasts range from $12.00 to $12.00. On average, they predict the company's stock price to reach $12.00 in the next year. This suggests a possible upside of 593.6% from the stock's current price.
View analysts price targets for AGRX
or view top-rated stocks among Wall Street analysts.

How have AGRX shares performed in 2023?

Agile Therapeutics' stock was trading at $0.2270 at the beginning of 2023. Since then, AGRX stock has increased by 662.1% and is now trading at $1.73.
View the best growth stocks for 2023 here
.

Are investors shorting Agile Therapeutics?

Agile Therapeutics saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 10,700 shares, a drop of 48.3% from the August 15th total of 20,700 shares. Based on an average daily trading volume, of 119,400 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.6% of the shares of the company are sold short.
View Agile Therapeutics' Short Interest
.

When is Agile Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our AGRX earnings forecast
.

How were Agile Therapeutics' earnings last quarter?

Agile Therapeutics, Inc. (NASDAQ:AGRX) posted its quarterly earnings results on Wednesday, August, 9th. The specialty pharmaceutical company reported ($3.10) earnings per share for the quarter, beating the consensus estimate of ($3.48) by $0.38. The specialty pharmaceutical company had revenue of $5.50 million for the quarter, compared to analyst estimates of $4.68 million. Agile Therapeutics had a negative trailing twelve-month return on equity of 2,658.43% and a negative net margin of 201.02%.

When did Agile Therapeutics' stock split?

Agile Therapeutics shares reverse split before market open on Wednesday, April 27th 2022. The 1-40 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What guidance has Agile Therapeutics issued on next quarter's earnings?

Agile Therapeutics issued an update on its FY 2023 earnings guidance on Thursday, August, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $25.00 million-$30.00 million, compared to the consensus revenue estimate of $21.66 million.

What other stocks do shareholders of Agile Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agile Therapeutics investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Nabriva Therapeutics (NBRV), AcelRx Pharmaceuticals (ACRX), Micron Technology (MU) and Novavax (NVAX).

What is Agile Therapeutics' stock symbol?

Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX."

Who are Agile Therapeutics' major shareholders?

Agile Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include State Street Corp (1.10%). Insiders that own company stock include Alfred Altomari, Dennis Reilly, Jason Butch and Perceptive Advisors Llc.
View institutional ownership trends
.

How do I buy shares of Agile Therapeutics?

Shares of AGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Agile Therapeutics' stock price today?

One share of AGRX stock can currently be purchased for approximately $1.73.

How much money does Agile Therapeutics make?

Agile Therapeutics (NASDAQ:AGRX) has a market capitalization of $3.34 million and generates $10.88 million in revenue each year. The specialty pharmaceutical company earns $-25,410,000.00 in net income (profit) each year or ($39.56) on an earnings per share basis.

How can I contact Agile Therapeutics?

Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The official website for the company is www.agiletherapeutics.com. The specialty pharmaceutical company can be reached via phone at (609) 683-1880 or via email at info@agiletherapeutics.com.

This page (NASDAQ:AGRX) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -